Merck & Co., Inc. (MRK) stock
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30285% above fair value
$144.46−3.30 (-2.23%)
Close on Nov 16, 2026Market cap $356.41BP/E 115.6Yield 2.27%
Merck r&d expenses
Research and development expenses are spending on new products and technology.
Merck's R&D Expenses for the twelve months ending Jun 30, 2026 was $30.45B, up 68.1% year over year. For fiscal 2025 it was $15.79B, down 12.0% from the year before. Over ten years it grew 8.9% a year on average. The highest annual figure on record is $30.53B in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.79B | -12.0% |
| FY2024 | Dec 31, 2024 | $17.94B | -41.2% |
| FY2023 | Dec 31, 2023 | $30.53B | +125.4% |
| FY2022 | Dec 31, 2022 | $13.55B | +10.6% |
| FY2021 | Dec 31, 2021 | $12.25B | -8.6% |
| FY2020 | Dec 31, 2020 | $13.40B | +37.8% |
| FY2019 | Dec 31, 2019 | $9.72B | -0.3% |
| FY2018 | Dec 31, 2018 | $9.75B | -5.7% |
| FY2017 | Dec 31, 2017 | $10.34B | +0.8% |
| FY2016 | Dec 31, 2016 | $10.26B | +53.1% |
| FY2015 | Dec 31, 2015 | $6.70B | -6.6% |
| FY2014 | Dec 31, 2014 | $7.18B | -4.3% |
| FY2013 | Dec 31, 2013 | $7.50B | -8.1% |
| FY2012 | Dec 31, 2012 | $8.17B | -3.5% |
| FY2011 | Dec 31, 2011 | $8.47B | -23.8% |
| FY2010 | Dec 31, 2010 | $11.11B | +90.1% |
| FY2009 | Dec 31, 2009 | $5.85B | +21.6% |
| FY2008 | Dec 31, 2008 | $4.81B | -1.6% |
| FY2007 | Dec 31, 2007 | $4.88B | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.74B | +140.6% |
| Q1 FY2026 | Mar 31, 2026 | $12.59B | +247.7% |
| Q4 FY2025 | Dec 31, 2025 | $3.89B | -15.2% |
| Q3 FY2025 | Sep 30, 2025 | $4.23B | -27.8% |
| Q2 FY2025 | Jun 30, 2025 | $4.05B | +15.7% |
| Q1 FY2025 | Mar 31, 2025 | $3.62B | -9.3% |
| Q4 FY2024 | Dec 31, 2024 | $4.58B | -52.4% |
| Q3 FY2024 | Sep 30, 2024 | $5.86B | +77.3% |
| Q2 FY2024 | Jun 30, 2024 | $3.50B | -73.7% |
| Q1 FY2024 | Mar 31, 2024 | $3.99B | -6.6% |
| Q4 FY2023 | Dec 31, 2023 | $9.63B | +155.0% |
| Q3 FY2023 | Sep 30, 2023 | $3.31B | -24.8% |
| Q2 FY2023 | Jun 30, 2023 | $13.32B | +376.1% |
| Q1 FY2023 | Mar 31, 2023 | $4.28B | +66.0% |
| Q4 FY2022 | Dec 31, 2022 | $3.78B | +23.0% |
| Q3 FY2022 | Sep 30, 2022 | $4.40B | +79.9% |
| Q2 FY2022 | Jun 30, 2022 | $2.80B | -35.2% |
| Q1 FY2022 | Mar 31, 2022 | $2.58B | +6.8% |
| Q4 FY2021 | Dec 31, 2021 | $3.07B | -47.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.45B | -27.0% |
| Q2 FY2021 | Jun 30, 2021 | $4.32B | +107.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.41B | +9.2% |
| Q4 FY2020 | Dec 31, 2020 | $5.79B | +141.2% |
| Q3 FY2020 | Sep 30, 2020 | $3.35B | +4.5% |
| Q2 FY2020 | Jun 30, 2020 | $2.09B | -4.8% |
| Q1 FY2020 | Mar 31, 2020 | $2.21B | +14.4% |
| Q4 FY2019 | Dec 31, 2019 | $2.40B | +8.4% |
| Q3 FY2019 | Sep 30, 2019 | $3.20B | +54.9% |
| Q2 FY2019 | Jun 30, 2019 | $2.19B | -3.7% |
| Q1 FY2019 | Mar 31, 2019 | $1.93B | -39.6% |
| Q4 FY2018 | Dec 31, 2018 | $2.21B | -4.4% |
| Q3 FY2018 | Sep 30, 2018 | $2.07B | -53.1% |
| Q2 FY2018 | Jun 30, 2018 | $2.27B | +27.6% |
| Q1 FY2018 | Mar 31, 2018 | $3.20B | +74.6% |
| Q4 FY2017 | Dec 31, 2017 | $2.32B | -51.6% |
| Q3 FY2017 | Sep 30, 2017 | $4.41B | +165.2% |
| Q2 FY2017 | Jun 30, 2017 | $1.78B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.83B | – |
| Q4 FY2016 | Dec 31, 2016 | $4.79B | – |
| Q3 FY2016 | Sep 30, 2016 | $1.66B | – |
See a number that looks wrong?